Navigation Links
Genoptix Reports Strong Growth for the First Quarter of 2009
Date:4/30/2009

. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

                            (Financial tables follow)


                                  GENOPTIX, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)
                      (in thousands, except per share data)

                                                   Three Months Ended
                                                        March 31,
                                                   2009           2008
    Revenues                                     $39,189        $22,298
    Cost of revenues                              15,429          9,175
    Gross profit                                  23,760         13,123
    Operating expenses:
      Sales and marketing                          6,990          4,261
      General and administrative                   6,390          4,388
      Research and development                       240            317
    Total operating expenses                      13,620          8,966
    Income from operations                        10,140          4,157
    Interest and other income                        501            959
    Income before income taxes                    10,641          5,116
    Income tax expense                             4,699            109
    Net income                                    $
'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... MADISON, Wis., and BIRMINGHAM, Ala., Sept. 14 ... is now offering a specialized,professional liability program ... being made available through Physicians Insurance Company,of ... "We are pleased to have the ...
... (HealthDay News) -- It,s under your movie seat and glued ... relief may be in sight. This week, researchers say they,ll ... at the BA Festival of Science in York, England. , ... and sidewalks, and preliminary tests indicate that it degrades naturally ...
... STAUNTON, Va., Sept. 14 Michael Bond has,been ... joins,the company following nearly 30 years in various ... Director of Blade Process,Engineering. Bond has a wealth ... advancement of leading edge technologies for,IncisionTech and Specialty ...
... Sept. 14 Stryker,Corporation (NYSE: SYK ) announced ... September 25, 2007 - 4:30 p.m. Eastern Time ... New York A simultaneous webcast of the Company,s ... via the For Investors page. The,presentation for the ...
... Sept. 14 Most people looking for tax advice,usually ... usually see,mechanics, right? Here,s more on a new report ... and questions are actually not seeing the pros,trained in ... at:, http://media.medialink.com/WebNR.aspx?story=33829 Registered journalists can access video, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced ... of Senior Vice President and Chief Compliance Officer. ... where she was,Director of Compliance for Latin America, ... for all compliance-related matters in those,regions. Prior to ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , , ... Orphan Drug Designation , SILVER SPRING, Md., Dec. 23 ... more transparent and accessible, the FDA has scheduled a series of ... unfamiliar with the process. The FDA can grant a special status, ...
... , , PHILADELPHIA, Dec. 23 URL Pharma today announced ... initiative designed to save patients money on their health insurance co-payment ... no more than $25 for a Colcrys prescription, which equates to ... the prevention and treatment of gout flares and for the treatment ...
Cached Medicine Technology:FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 3URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 4
...
... System is a complete anterior ... portable, it offers high-end performance ... console. It also provides all ... segment surgery. These include Irrigation, ...
... tool designed for ophthalmic surgeons. ... reliable, safe and easy to ... (one year for ultrasonic handpiece). ... console, phaco handpiece, foot pedal, ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: